MARKET

NURPF

NURPF

Neuren Pharma
OTCPK
8.22
NaN%
Closed 09:30 04/02 EDT
OPEN
--
PREV CLOSE
8.22
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
15.15
52 WEEK LOW
6.60
MARKET CAP
1.04B
P/E (TTM)
52.93
1D
5D
1M
3M
1Y
5Y
1D
Neuren Pharmaceuticals Reports Lapse of 50,000 Conditional Options
TipRanks · 03/26 07:49
Neuren Updates Market on Ongoing On-Market Share Buy-Back
TipRanks · 03/12 21:57
Neuren director Joseph Basile lifts stake with on-market share purchase
TipRanks · 03/05 23:33
Macquarie Sticks to Their Buy Rating for Neuren Pharmaceuticals Limited (NURPF)
TipRanks · 03/03 22:35
Neuren backs Acadia’s EMA appeal after CHMP rejection of Rett drug trofinetide
TipRanks · 03/02 23:34
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF), Mesoblast Limited (OtherMEOBF) and Ramsay Health Care (OtherRMSYF)
TipRanks · 03/01 23:10
Neuren Highlights Neurodevelopmental Focus and Development Risks in Investor Update
TipRanks · 02/27 01:37
Neuren Builds Cash and Pipeline as DAYBUE Royalties Climb in 2025
TipRanks · 02/27 01:08
More
About NURPF
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product, NNZ-2591, is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

Webull offers Neuren Pharmaceuticals Ltd stock information, including OTCPK: NURPF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURPF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NURPF stock methods without spending real money on the virtual paper trading platform.